All patients
age >= 65 yr omicron variant BA.1 (B.1.1.529) solid organ transplant recipients subjects at risk
neutralizing antibody in COVID 19 outpatients - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results COMET-ICE, 2021 0.25 [0.01; 5.55]
CT-P59 3.2 part 2, 2021 0.50 [0.05; 5.54]
0.39 [0.06 ; 2.58 ] COMET-ICE, 2021, CT-P59 3.2 part 2, 2021 2 0% 2,372 NA not evaluable deathsdetailed results ACTIV-2 (BRII-196 and BRII-198), 0 0.05 [0.00; 0.94]
BLAZE-1 phase 3 (combo), 2021 0.05 [0.00; 0.84]
COMET-ICE, 2021 0.25 [0.01; 5.55]
Cov-2067 Weinreich (1200mg) Cohort 1, 2020 0.45 [0.05; 3.82]
Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 1.01 [0.02; 51.05]
0.19 [0.05 ; 0.67 ] ACTIV-2 (BRII-196 and BRII-198), 0, BLAZE-1 phase 3 (combo), 2021, COMET-ICE, 2021, Cov-2067 Weinreich (1200mg) Cohort 1, 2020, Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 5 0% 5,910 low not evaluable hospitalization or deathdetailed results ACTIV-2 (BRII-196 and BRII-198), 0 0.22 [0.05; 0.91]
BLAZE-1 phase 2 (combination with etesevimab), 2020 0.15 [0.02; 1.18]
BLAZE-1 phase 2 (monotherapy), 2020 0.16 [0.02; 1.31]
BLAZE-1 phase 3 (combo), 2021 0.29 [0.15; 0.58]
COMET-ICE, 2021 0.21 [0.09; 0.49]
Cov-2067 Weinreich (1200mg) Cohort 1, 2020 0.29 [0.12; 0.68]
CT-P59 3.2 part 1, 2021 0.48 [0.19; 1.25]
CT-P59 3.2 part 2, 2021 0.29 [0.16; 0.51]
TACKLE, 0 0.47 [0.26; 0.84]
0.32 [0.24 ; 0.42 ] ACTIV-2 (BRII-196 and BRII-198), 0, BLAZE-1 phase 2 (combination with etesevimab), 2020, BLAZE-1 phase 2 (monotherapy), 2020, BLAZE-1 phase 3 (combo), 2021, COMET-ICE, 2021, Cov-2067 Weinreich (1200mg) Cohort 1, 2020, CT-P59 3.2 part 1, 2021, CT-P59 3.2 part 2, 2021, TACKLE, 0 9 0% 6,545 low not evaluable clinical deteriorationdetailed results COMET-ICE, 2021 0.24 [0.10; 0.56]
0.24 [0.10 ; 0.56 ] COMET-ICE, 2021 1 0% 1,057 NA not evaluable clinical improvement (time to event analysis only)detailed results CT-P59 3.2 part 2, 2021 1.50 [1.30; 1.74]
1.50 [1.30 ; 1.74 ] CT-P59 3.2 part 2, 2021 1 0% 1,315 NA not evaluable hospitalizationdetailed results COMET-ICE, 2021 0.20 [0.08; 0.48]
Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 0.08 [0.00; 1.49]
0.18 [0.08 ; 0.43 ] COMET-ICE, 2021, Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 2 0% 1,261 low not evaluable Recovery (time to event analysis only)detailed results CT-P59 3.2 part 2, 2021 1.50 [1.30; 1.74]
1.50 [1.30 ; 1.74 ] CT-P59 3.2 part 2, 2021 1 0% 1,315 NA not evaluable symptomatic Covid-19detailed results Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 0.56 [0.31; 1.00]
0.56 [0.31 ; 1.00 ] Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 1 0% 204 NA not evaluable viral clearance detailed results BLAZE-1 phase 2 (combination with etesevimab), 2020 1.65 [0.91; 3.00]
BLAZE-1 phase 2 (monotherapy), 2020 0.67 [0.33; 1.38]
1.08 [0.45 ; 2.60 ] BLAZE-1 phase 2 (combination with etesevimab), 2020, BLAZE-1 phase 2 (monotherapy), 2020 2 72% 470 moderate not evaluable viral clearance by day 7detailed results BLAZE-1 phase 2 (combination with etesevimab), 2020 1.31 [0.61; 2.83]
BLAZE-1 phase 2 (monotherapy), 2020 0.91 [0.39; 2.09]
BLAZE-4, 0 0.37 [0.20; 0.66]
0.73 [0.33 ; 1.64 ] BLAZE-1 phase 2 (combination with etesevimab), 2020, BLAZE-1 phase 2 (monotherapy), 2020, BLAZE-4, 0 3 73% 771 low not evaluable emergent treatment-resistant variantsdetailed results BLAZE-1 phase 2 (combination with etesevimab), 2020 0.18 [0.02; 1.51]
BLAZE-1 phase 2 (monotherapy), 2020 1.52 [0.51; 4.47]
0.64 [0.08 ; 4.94 ] BLAZE-1 phase 2 (combination with etesevimab), 2020, BLAZE-1 phase 2 (monotherapy), 2020 2 67% 497 moderate not evaluable serious adverse eventsdetailed results Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 0.25 [0.03; 2.23]
0.25 [0.03 ; 2.23 ] Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 1 0% 311 NA not evaluable adverse eventsdetailed results COMET-ICE, 2021 0.91 [0.68; 1.22]
Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 0.55 [0.34; 0.86]
0.73 [0.44 ; 1.20 ] COMET-ICE, 2021, Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021 2 71% 1,360 low not evaluable 0.0 2.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-01 10:14 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 97
- treatments: 729,887,742,878,975,570,771,888,1141,690,880,1255
- roots T: 290
